Truist Financial Corp Corcept Therapeutics Inc Transaction History

Truist Financial Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$21.1 - $27.46 $116,197 - $151,222	-5,507 Reduced 37.33%	9,246 $232,000
Q4 2023 Feb 02, 2024	SELL	$24.82 - $32.88 $93,720 - $124,154	-3,776 Reduced 20.38%	14,753 $479,000
Q3 2023 Nov 14, 2023	BUY	$21.97 - $33.8 $191,380 - $294,431	8,711 Added 88.72%	18,529 $504,000
Q2 2023 Aug 01, 2023	SELL	$21.44 - $25.15 $462,675 - $542,737	-21,580 Reduced 68.73%	9,818 $218,000
Q1 2023 May 05, 2023	BUY	$19.2 - $24.47 $170,131 - $216,828	8,861 Added 39.32%	31,398 $680,000
Q4 2022 Feb 17, 2023	BUY	$19.95 - $29.96 $449,613 - $675,208	22,537 New	22,537 $457,000
Q4 2021 Feb 14, 2022	BUY	$17.1 - $23.34 $261,544 - $356,985	15,295 New	15,295 $303,000
Q4 2020 Feb 18, 2021	SELL	$16.78 - $27.3 $471,182 - $766,584	-28,080 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$12.46 - $19.98 $56,568 - $90,709	-4,540 Reduced 13.92%	28,080 $489,000
Q2 2020 Aug 14, 2020	SELL	$11.0 - $18.26 $42,119 - $69,917	-3,829 Reduced 10.51%	32,620 $549,000
Q1 2020 May 15, 2020	SELL	$10.11 - $14.04 $41,784 - $58,027	-4,133 Reduced 10.18%	36,449 $433,000
Q4 2019 Feb 14, 2020	BUY	$12.06 - $16.96 $489,418 - $688,270	40,582 New	40,582 $491,000

355

86.2M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $7.17B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.